Jinbin Zh AI
About Jinbin Zh AI
Jinbin Zh is a Drug Discovery Scientist at Bristol Myers Squibb with extensive experience in gene therapy and virus production.
Title
Jinbin Zh AI is currently positioned as a Drug Discovery Scientist at Bristol Myers Squibb in Princeton, New Jersey, United States. The role involves innovative research and development in the field of pharmaceutical sciences.
Previous Roles
Prior to joining Bristol Myers Squibb, Jinbin Zh AI served as a Senior Research Investigator at the Gene Therapy Program at the University of Pennsylvania from 2017 to 2018. From 2013 to 2017, he was an Associate Scientist at Temple University. Earlier in his career, he worked as a Research Scientist at The Children's Hospital of Philadelphia for six years. His professional journey also includes an eight-year stint as a Research Associate at the University of Pennsylvania School of Medicine from 1999 to 2007.
Education and Expertise
Jinbin Zh AI earned his Doctor of Philosophy (Ph.D.) in Gene/Genetic Therapy from Peking Union Medical College, completing his studies from 1994 to 1998. His academic background equips him with advanced knowledge in gene therapy, specifically in vector design and optimization, a crucial aspect of his research endeavors.
Gene Therapy Contributions
Jinbin Zh AI has led preclinical studies focusing on AAV-mediated gene delivery for Duchenne Muscular Dystrophy. He has considerable hands-on experience in virus production and characterization. His expertise extends to designing and optimizing gene therapy vector cassettes targeting different tissues and organs. He has also established and implemented bioanalytical assays for therapeutic genes.
Team Management and Collaboration
Jinbin Zh AI is skilled in managing teams of scientists and collaborating with external Contract Research Organizations (CROs) to achieve project goals. His leadership and coordination efforts are instrumental in advancing research projects in gene therapy and drug discovery.